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Abstract 
This study examined the relative effectiveness of VSM and exposure in treating public speaking 
anxiety in reducing anxiety with a college student. The study employed a single-subject A-B 
design with parametric variations. Two phases were utilized in this study: baseline (exposure 
therapy) and treatment (video self-modeling) with a one-month follow-up. Generalization probes 
were also employed to assess whether or not decreases in PSA would generalize to other settings. 
Results indicate a significant decrease in public speaking anxiety from both pre- to post-
treatment as well as from baseline to exposure. However, these results may be specific to public 
speaking anxiety, as other forms of anxiety did not result in such decreases. Results from a post-
treatment survey indicated that the participant felt that the treatment was beneficial in reducing 
public speaking anxiety.  
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Introduction 
Social Anxiety Disorder 
 Overview. Social anxiety disorder (SAD) is one of the most common anxiety disorders, 
and it is characterized by an intense fear of social situations in which the individual may be 
judged by others (American Psychiatric Association, 2013). Social anxiety disorder affects 
approximately 7% of the United States population with onset typically occurring during 
adolescence. Many individuals "grow out" of the disorder, but, for those who do not, the disorder 
tends to be chronic and causes pervasive impairment. Individuals with SAD are at risk for 
decreased rates of workplace productivity, increased rates of unemployment and social isolation, 
and lower quality of life. Only about half of individuals suffering from social anxiety disorder 
seek treatment, and they generally experience life-long impact, such as comorbid affective 
disorders and other anxiety disorders. 
 There are multiple ways to develop social anxiety disorder. Operant conditioning theory 
suggests that individuals develop SAD due to predictable punishment after social behavior (e.g., 
experiencing bullying when trying to make new friends) or due to reinforcement after solitary 
behavior (e.g., reduce anxiety by sitting alone). Most individuals experience these consequences 
of behavior, but few go on to develop clinical levels of social anxiety. For some individuals, the 
experience may be very strong or, to use the term colloquially, traumatic. When an individual 
experiences this "traumatic" event, further behavioral consequences (i.e., reinforcement or 
punishment) may not be needed. Similarly, social learning theory posits that an individual will 
learn to be asocial by seeing someone else experience the situations mentioned above (Bandura, 
1969). 
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  Anxiety is generally maintained by the processes escape and avoidance, and someone 
who regularly avoids situations that make him uncomfortable can be differentially reinforcing 
himself to engage in solitary behaviors. Social anxiety may also be generalized to other types of 
anxiety. For example, many individuals who exhibit signs of SAD can go on to develop 
generalized anxiety disorder (Leary & Kowalski, 1995). On the other hand, an individual with 
SAD may discriminate his experiences to only being afraid of performing in front of others. This 
performance-only type of social anxiety is described in the DSM-5 as a social fear limited to 
performing (giving speeches, dancing, etc.) in front of others which may cause impairment in 
work or academic settings (APA, 2013).    
 Treatments. There is a multitude of treatment options, and among the most common 
type is biological medication. Selective serotonin reuptake inhibitors (SSRIs) are the most 
commonly used biological treatment for anxiety, and most patients seem to respond well to these 
drugs (Beidel & Turner, 2007). However, some patients may still fail to improve while taking 
these medications. For these unresponsive patients, alternatives such as benzodiazepines and 
monoamine oxidase inhibitors (MAOIs) are available although these drugs may be accompanied 
by severe side effects and limitations, including psychological and physical dependence and 
restrictive diet. Although biological interventions are highly effective for treating conditions, the 
effects of treatment do not tend to be longstanding. In fact, according to Beidel and Turner 
(2007), the effects of biological treatment do not persist beyond treatment termination.  
 Although biological treatments show some benefits, the majority of research has 
demonstrated the efficacy of behavioral and cognitive-behavioral treatments (Beidel & Turner, 
2007). Simple exposure therapy seems to play a vital role in reducing social anxiety. Direct 
VSM TREATMENT OF SPEECH ANXIETY  7 
 
experience seems to play the most important role in learning which supports the use of exposure 
in treatment (Bandura, 1977).  
 Cognitive restructuring, when paired with exposure therapy, is the basis for the class of 
treatments known as cognitive-behavioral therapy (CBT). According to Leary and Kowalski 
(1995), anxious cognitions are primary to social anxiety disorder. Thus, a cognitively-based 
disorder can seldom be treated by behavioral techniques alone. In fact, cognitive therapies are 
most commonly used for treating social anxiety disorder. Behaviorally-based treatments fall 
further behind in commonality after both cognitive therapies and social skills training. However, 
one theoretical orientation may not always be the most effective means of treatment. For 
example, cognitive restructuring, when paired with exposure therapy, provides numerous 
advantages over other forms of treatment, such as behavioral and biological, including higher 
quality of life, reduced social anxiety, and improved life satisfaction (Leary & Kowalski, 1995).  
  Some other forms of treatment may also show promise in the treatment of social anxiety 
disorder. There is support for the use of mindfulness training in combination with exposure 
therapy (Rubin, 2009). Social skills training, a largely behavioral intervention is also rather 
effective at reducing social anxiety, especially when it is used in combination with another 
technique (Beidel & Turner, 2007).  
 However, there is still some disagreement as to which form of therapy may be most 
effective for SAD. For example, Leary and Kowalski (1995) state that behavioral treatments do 
not sufficiently improve cognitions of individuals suffering with SAD. However, Beidel and 
Turner (2007) disagree. Beidel and Turner (2007) further state that exposure provides significant 
change in social anxiety that is not necessarily improved by implementing another aspect to 
treatment, such as cognitive restructuring. 
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Public Speaking Anxiety 
 Overview. Approximately 20% of people report an excessively high degree of anxiety 
when speaking in public (Leary & Kowalski, 1995). In college student populations, as many as 
35% of people report at least a moderate need for assistance with public speaking anxiety 
(Bishop, Bauer, & Becker, 1998). These rates are even higher among individuals with SAD, with 
approximately 97 percent of people who report feeling distressed by public speaking (Beidel & 
Turner, 2007).  
 Although PSA and SAD have similar origins, research suggests that public speaking 
anxiety is distinct from social anxiety disorder, in that individuals who are apprehensive about 
public speaking may exhibit PSA while failing to endorse any other symptoms of social anxiety 
(Blőte, Kint, Miers, & Westenberg, 2009). Further supporting this notion, Blőte and colleagues 
(2009) found that individuals with PSA are more similar to non-anxious controls than to 
individuals with SAD in terms of overall anxiety. Although PSA is more commonly experienced 
by individuals with social anxiety disorder as compared to non-anxious individuals, individuals 
who are only experiencing impairment due to PSA are less likely to seek treatment. These 
individuals are less likely to seek treatment because the impairments due to PSA are less 
extensive than the impairments experienced by individuals with SAD.  
 There are many factors that may influence speech-anxious individuals that do not 
necessarily impact the general public in the same way. For example, research suggests that 
individuals with high levels of speech anxiety are more likely than individuals with lower levels 
of speech anxiety to be sensitive to facial expressions displayed by others (Dimberg & Thunberg, 
2007). This finding plays a direct role in implementing a VSM treatment of speech anxiety. 
Audience facial characteristics can influence the performance of speakers. In order to reduce as 
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much influence as possible, audience members should maintain neutral facial expressions in 
order to avoid influencing the performer.  
 Measuring public speaking anxiety without the use of self-report measures can be 
complex. Though there are some tools that measure physiological aspects of PSA, there are few 
means for measuring behavioral representations of anxiety. Speech dysfluencies are common 
behavioral manifestations of social anxiety, and they can be measured through direct 
observation. Anxious individuals are more likely to stutter or have other verbal dysfluencies, 
repeat themselves, use verbal crutches, implement unnecessary pauses, have substandard 
memory, blush, and have overall poorer communication skills than non-anxious individuals 
(Leary & Kowalski, 1995). By using direct observation to measure these manifestations, 
researchers can better understand and track treatment outcomes.  
 Treatments. The treatment of PSA has been thoroughly addressed in the treatment 
outcome literature. Although a large proportion of the population reports speech anxiety as a 
concern, most people do not seek treatment (Leary & Kowalski, 1995). However, there are 
serious implications for not treating PSA, specifically in the college community. For example, 
many universities require students to take specific classes to develop their speech skills, and 
many upper-level courses require presentations. Individuals suffering from speech anxiety may 
face negative consequences including, but not limited to, poorer grades and embarrassment. 
Therefore, treating PSA is vital, and treatment should occur earlier in the lifespan in order to 
reduce negative outcomes.  
 Many of the treatments for PSA are similar to those common of social anxiety disorder. 
Specifically, behavior therapy and cognitive-behavior therapy are among the most common 
interventions. Exposure, a form of behavioral therapy is generally quite effective at reducing 
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anxiety, even when this treatment stands alone (i.e., without any cognitive restructuring; 
Richman, 1995). In order to extend the effects of treatment, Tsao and Craske (2000) suggest 
expanding the treatment schedule. This involves scheduling sessions further apart (e.g., 5 days, 7 
days, 10 days) in order to reduce spontaneous recovery of PSA. 
 Social impact theory posits that speech anxiety can be explained by both social 
desirability and audience size (Beatty & Payne, 1983). Specifically, individuals are more likely 
to experience speech anxiety in the presence of a large audience and desire for social approval. 
Although an individual's desire for social approval cannot be directly modified as an independent 
variable, audience size can be controlled in order to reduce anxiety levels as much as possible.  
 Although there is some discord among researchers as to which type of therapy is most 
effective in treating PSA, Sefchick, (1987) found that cognitive behavioral therapy, an example 
of which is VSM, is more effective than both exposure therapy and cognitive restructuring on 
their own. Some other aspects that may enhance therapy are peer feedback, positive thinking, 
and skills training (Ayers, 1988; Hayes & Marshall, 1984; Lawm, Schwartz, Houlihan, & 
Cassisi, 1994). 
Video Self-Modeling 
 Overview. Video self-modeling (VSM) is defined as, "the behavioral change that results 
from the observation of oneself on videotape that show only desired target behaviors" (Dowrick 
& Biggs, 1983, p. 105). The theoretical support for VSM lies in Bandura's social learning theory. 
Reciprocal determinism, the basis of social learning theory, posits that the individual's behavior 
influences the environment and that the environment influences the individual's behavior 
(Bandura, 1977). One key element of observational learning is the similarity between the model 
and the observer (Dowrick & Biggs, 1983). Because the model and observer are the same person, 
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VSM embodies the similarity between the model and observer, thus making the observer more 
likely to reproduce the desirable behaviors that the model originally produced.  
 According to Dowrick and Biggs (1983), self-modeling is an effective technique, but 
there are steps that researchers and clinicians should take when implementing VSM. The major 
concern to address in VSM is the use of edited video. Because having participants watch 
themselves make mistakes can be detrimental to the therapeutic process, videos should be edited 
to remove behavioral dysfluencies (e.g. stuttering, unnecessary pauses) and other unflattering 
physiological reactions (e.g. blushing, heavy breathing). The edited videos exemplify a major 
aspect of treatment of social anxiety disorder: cognitive change. By individuals observing only 
positive aspects of their performances and being unable to attend to negative aspects of behavior, 
which is a major maintaining factor in SAD, cognitive change is occurring (Beidel & Turner, 
2007). However, it is important to have the video seem realistic so that the client does not lose 
trust (Dowrik & Biggs, 1983). 
 VSM has been used to treat an array of issues including enhancing appropriate verbal 
responses in children with autism, improving swimming in children with spina bifida, increasing 
verbal responding in a child with selective mutism, increasing math skills in general education 
classrooms, and increasing appropriate social behavior among children with developmental and 
behavior disorders (Dowrick & Dove, 1980; Hitchcock, Dowrick, & Prater, 2003). The results of 
these studies demonstrate that VSM can be used to treat a variety of issues. An advantage of this 
single-subject research is that individuals can be treated quickly with individual results 
composing the data.  
 History of Use with PSA. The use of VSM to treat public speaking anxiety is fairly new, 
and results of the research is mixed. Kruger (2013) failed to find significant decreases in self-
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report anxiety between exposure and VSM conditions. Likewise, the results of behavioral 
manifestations of PSA were mixed with one participant showing significant decreases in speech 
dysfluencies while the results from the other participant demonstrated an increase in speech 
dysfluencies.  
 Contrary to Kruger' findings, Poppenga (1996) found significant decreases in self-report 
public speaking anxiety from baseline to treatment conditions. Poppenga found further support 
for VSM treatment through reductions in state anxiety and subjective discomfort. Results of 
behavioral manifestations of PSA were mixed, with some participants demonstrating 
improvement and other demonstrating stability or deterioration. Although the data show 
improvement from pre-treatment to post-treatment, it does not seem that VSM plays a role in the 
reductions. Rather, it seems as though exposure is the primary cause for reductions in self-report 
anxiety scores.  
 Rickards-Schlichting (2004) also found significant decreases in self-report speech anxiety 
from baseline to treatment phases. However, because this study employed an A-B design as 
opposed the multiple baseline design used by Kruger and Poppenga, there is serious threat to 
validity that need to be addressed. The A-B design fails to rule out the influence of history. 
Although the results of this study are not necessarily robust, a major advantage of this study is 
the population studied. Although most research on the topic of PSA involves young college 
students (e.g., Kruger and Poppenga), this study established generality by having participants 
who were in high school. By studying this population, Rickards-Schlichting established that 
VSM treatment of public speaking anxiety can successfully be generalized to younger 
populations. However, the question remains if this treatment can sufficiently be generalized to 
older populations.  
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 Treatment targets of early VSM research included increasing appropriate classroom 
behaviors. More recently, VSM has been used to treat other, more complex tasks. VSM to treat 
public speaking anxiety is a growing area of interest, however, the studies done in this area tend 
to use college students recruited from their regular classrooms. Unfortunately, it is unclear 
whether VSM treatment of PSA is advantageous for other populations.  
Method 
Participants 
 Flyers were posted throughout the community advertising a free treatment for public 
speaking anxiety. Thus, participants were recruited from various locations throughout a 
Midwestern community. Interested individuals were instructed to contact the researchers with 
provided contact information and were invited to attend a screening session to determine if the 
individual met inclusion criteria for the study.  
 Individuals who were interested in treatment were administered the Personal Report of 
Confidence as a Speaker-Short Form (PRCS-12; Hook, Smith, & Valentiner, 2008) in an initial 
screening session. The PRCS-12 was used as the primary screening measure. Because there is no 
agreed upon cutoff score, a score in the 67th percentile (a score of 8 out of 12) was used to 
ensure that the individuals screened were truly suffering from public speaking anxiety.  
 Three individuals attended screening sessions and met inclusion criteria. However, two of 
the participants dropped out of the study for personal reasons, yielding a single participant. The 
participant was a 19-year-old female attending school at a mid-sized Midwestern university. She 
endorsed significant public speaking anxiety, scoring a 10 out of 12 on the PRCS in the 
screening session.  
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Instruments 
 At the first and final sessions, the Social Interaction Anxiety Scale (SIAS) was 
administered. The SIAS is a 19-item self-report scale that measures social anxiety. Two of the 
items on this scale are reverse coded. This scale was developed by Mattick and Clarke (1998) by 
combining social anxiety inventories and newly created items based on information obtained 
from clinical interviews with individuals with SAD. The most predictive 19 items from the 
original 164 items were selected for use. The SIAS demonstrates high internal consistency 
(α=.90) and fair convergent validity (r = .41-.72; Brown et al., 1997; Osman, Gutierrez, Barrios, 
Kopper, & Chiros, 1998). Sample items include, "I am tense mixing in a group," and "I find it 
difficult to disagree with another's point of view."  
 At each session, the PRCS-12 was administered. The PRCS-12 is a 12-item self-report 
measure that assesses speech anxiety. The current version of this scale, developed by Hook, 
Smith, and Valentiner (2008), was derived from the 30-item scale to include the 12 most 
predictive items. The PRCS-12 demonstrates good internal reliability (α=.85) and fair convergent 
validity (r = .15-.54; Hook, Smith, & Valentiner, 2008). Sample questions include, "While 
preparing a speech I am in a constant state of anxiety," and "My thoughts become confused and 
jumbled when I speak before an audience."  
 The Subjective Units of Discomfort Scale (SUDS; Shapiro, 1995) was completed 
immediately prior to each speech. The SUDS is a short scale that measures an individual's self-
report distress. SUDS scores have been found to be significantly negatively correlated with 
patients' global assessment of functioning (GAF) scores, (r = -0.439, p < .001; Tanner, 2012). 
SUDS scores have also been found to be related to MMPI scores, showing a significant 
relationship between SUDS and the neurotic index of the MMPI (r = 0.366, p < .01). The SUDS 
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has also been found to effectively track treatment outcomes, with results demonstrating reduction 
in SUDS scores after 3 months of psychotherapy (t = -4.686, p < .001; Tanner, 2012). 
 Direct observation was used to record speech dysfluencies during each session. Although 
the literature suggests using momentary time sampling, some of the behaviors measured relied 
upon duration measures. As a result, momentary time sampling was considered inappropriate, so 
partial interval recording was used to measure speech anxiety. Behaviors indicative of speech 
anxiety are presented in Table 1. Approximately 30 percent of observations were rated by two 
observers in order to assess inter-observer agreement. Using partial interval agreement, inter-
observer agreement was moderate, with an agreement rate of 86.2%.  
 In order to address the participant's perception of treatment, a short self-report survey was 
given at the final session of treatment. This questionnaire included items to assess perception and 
utility of treatment and any variables that may have served as anxiety-inducing or anxiety-
reducing confound (See Appendix A).  
Design 
 An A-B design with parametric variations was utilized in this study, with "A" indicating 
baseline or exposure therapy and "B" indicating treatment or video-self modeling. Because VSM 
is a type of learning, a withdrawal design would not be appropriate for determining the effects of 
the intervention. During the baseline phase, the participant first completed the PRCS and SUDS. 
Upon completion of these measures, the participant was allowed five minutes to review a pre-
written speech. After the five minute review period, the participant performed a 6-8 minute 
videotaped pre-written speech that was randomly selected from a speech bank. The participant 
was allowed the transcript and any notes she wrote during her speeches. Speech topics were over 
a range of general knowledge topics such as fast food consumption, tourist attractions, and social 
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networking. Speeches were recorded using a Canon Power Shot ELPH 300 HS digital camera. 
These video recordings were used for direct observation analysis and were edited as part of the 
VSM treatment package. Immediately after performing the speeches, the participant was 
reminded of his/her right to withdraw from treatment. In addition, a debriefing session was 
conducted in order to alleviate any temporary anxiety that the participant may be experiencing. 
Imagery training and progressive muscle relaxation were implemented as a part of the debriefing 
sessions.  
 The only change from baseline to treatment phase was that, in the treatment phase, the 
participant watched an edited videotape of the speech performed in the last session prior to 
completing self-report anxiety measures. Speeches were edited with the software CyberLink 
PowerDirector, in order to remove any speech dysfluencies. Speech dysfluencies removed are 
listed in Table 1. These videos were between 2-5 minutes, as suggested by Dowrick and Biggs 
(1983).   
 In order to test generalization, only the researcher was present for speeches. However, for 
two sessions, a larger audience, ranging from three to four people served as probes in order to 
ensure that treatment was able to generalize to a different audience. To further examine 
generalization, a follow-up session was conducted one month after treatment completion.   
Hypotheses 
 The major question in this area of research is whether or not exposure and VSM 
effectively treat anxiety. Within this question, there are five hypotheses that were tested to 
answer this question.  
 Hypothesis 1. Participants' Social Interaction Anxiety Scale scores will decrease from 
pre-treatment to post-treatment. This hypothesis will be used to determine if the combination of 
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treatments (exposure and VSM) effectively reduce social anxiety, which is commonly associated 
with public speaking anxiety.  
 Hypothesis 2. Participants' Personal Report of Confidence as a Speaker scores will 
decrease from pre-treatment to post-treatment. The purpose of this hypothesis is to determine if 
the combination of treatments effectively reduce public speaking anxiety.  
 Hypothesis 3. Participants' Personal Report of Confidence as a Speaker scores will be 
significantly lower in the treatment (VSM) phase than in the baseline (exposure) phase. This 
hypothesis is being used to verify the effectiveness of VSM at treating public speaking anxiety.  
 Hypothesis 4. Participants' Subjective Units of Discomfort Scale scores will be 
significantly lower in the treatment (VSM) phase than in the baseline (exposure) phase. The 
issue of concern with this hypothesis is if VSM is more effective than exposure at reducing 
anxiety levels immediately prior to giving speeches.  
 Hypothesis 5. Participants' direct observation scores (intervals indicative of PSA) will be 
significantly lower in the treatment (VSM) phase than in the baseline (exposure) phase. The 
purpose of this hypothesis is to determine if VSM is more effective than exposure in reducing 
behavioral manifestations of anxiety.  
Results 
 Overall, results indicate that the treatments were effective at reducing self-reported public 
speaking anxiety. However, results regarding other forms of anxiety (e.g., social and momentary 
distress) were mixed. A more detailed description of the results are presented below.  
Social Interaction Anxiety Scale 
 Prior to treatment, the participant endorsed a score of 25 out of 95 on the SIAS, 
suggesting the lack of presence of social anxiety disorder. At post-treatment, the participant 
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again endorsed a score of 25. This lack of change indicates that the treatment was unsuccessful at 
treating PSA, failing to provide support for hypothesis 1.  
Personal Report of Confidence as a Speaker 
 Prior to treatment, the participant endorsed a score of 8 out of 12 on the PRCS. At post-
treatment, the participant endorsed 4 out of the 12 items on the PRCS. This 50% decrease, which 
is the benchmark for clinically significant symptom reduction, indicates a significant decrease in 
PSA from pre- to post- treatment (Palermo, 2012). Thus, this decrease provides support for 
hypothesis 2. VSM did appear to be effective at reducing public speaking anxiety beyond the 
effects of exposure alone. These reductions suggest that the treatment was fairly effective, with 
PND (points of non-overlapping data) = 71.4%, providing support for hypothesis 3 (Scruggs, 
Mastropieri, Cook, & Escobar, 1986). These results are maintained, as suggested by results of 
the follow-up session. These results are presented in Figure 1. 
 
Figure 1. Participant scores on the Personal Report of Confidence as a Speaker. 
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Subjective Units of Discomfort Scale 
 VSM did not appear to be effective at reducing discomfort associated with public 
speaking anxiety. Statistical results suggest that this treatment was unreliable at reducing SUDS 
score, with  PND = 14.2 percent. Although there is a decrease in SUDS scores and this decreases 
is maintained, these results fail to support hypothesis 4. These results are presented in Figure 2.  
 
Figure 2. Participant scores on the Subjective Units of Discomfort Scale. 
Direct Observation 
 Treatment was ineffective at reducing behavioral manifestations of public speaking 
anxiety, with PND = 0.0%, failing to support hypothesis 5. In addition, these results are 
maintained, as indicated by the follow-up session (See Figure 3).  
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Figure 3. Participant percentage of intervals indicative of anxiety as measured by direct 
observation. 
Perception of Treatment 
 The participant indicated that the treatment was effective at reducing public speaking 
anxiety while also increasing participant confidence while giving speeches. In addition, the 
participant indicated that she would recommend the treatment to others experiencing public 
speaking anxiety. Overall, the participant's satisfaction with treatment was high which may have 
increased the effectiveness of treatment in general.  
 In addition, a secondary purpose of the perception of treatment survey was to measure 
any variables that may be influencing treatment outcomes. The participant indicated that there 
were no other factors that had influenced treatment outcomes. However, the participant did 
indicate that she had given a speech for a class (prior to session 8), and reductions in anxiety are 
apparent (see Figures 1 and 2).  
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Discussion 
 Results of this study suggest that public speaking anxiety may be treated with both 
behavioral and cognitive-behavioral interventions. In addition, results indicate that including 
cognitive change provides added benefits in treatment that were unlikely to occur from exposure 
alone. In addition, results were maintained at a one-month follow-up, suggesting that treatment 
provides long-term decreases in public speaking anxiety. However, these results are specific to 
public speaking anxiety as the only outcome measure that indicated decreases was the PRCS. 
Overall, the participant's satisfaction with treatment was high, suggesting that this treatment 
should be used in the future to treat individuals who experience anxiety associated with giving 
speeches. 
Limitations 
 This study has some noteworthy limitations. First, this study has a small sample size, and 
thus, the options for study design are limited. This study employed an A-B design that lacks the 
experimental control that would be provided in a multiple baseline design or a reversal design. 
However, a reversal design would not be appropriate given that the cognitive change of VSM is 
considered a type of learning. Furthermore, a multiple baseline design cannot be conducted with 
a single participant.  Results could be enhanced through replication with other subjects over time. 
 Another major limitation of this study is the lack of sensitivity in some of the measures. 
The SUDS used in this study was an 11-point measure, and the participant scored within a small 
range on this measure (0-3). In addition, the PRCS is only a 12-point measure. Although the 
participant did exhibit a larger range of scores (3-10, including screening session), this measure 
is also fairly insensitive to change.  
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 The debriefing session conducted at the end of each of session may have influenced 
results. Since relaxation skills were taught in this session, the participants may have utilized 
these techniques beyond the session which may have confounded the results. This may in fact be 
the case, as there is a notable decrease in PRCS and SUDS scores from the first to second 
session. Future research should be conducted without these debriefing sessions. 
 The major concern with this type of research is the trade-off between internal and 
external validity. Although an aim of this study was to capitalize on internal validity, this results 
in a lack of external validity that can result in data that are not meaningful. One area within this 
trade-off is the treatment setting. The participant gave speeches to a small audience, which is 
atypical of most presentation settings. Furthermore, because the speeches were pre-written, the 
participants were likely to read the speeches as opposed to performing the speeches. This may 
aid in explaining why the participant demonstrated higher levels of speech anxiety, as indicated 
through direct observation data, as treatment progressed.  
Future Research 
 Future research should be done in a more naturalistic setting. For example, recording 
sessions in classroom setting in which individuals already give speeches may produce more 
meaningful results. Because public speaking anxiety is a clinical issue, it is important that results 
from research are able to be generalized. Thus, it is important for future research to highlight the 
potential external validity of research. while also considering the importance of internal validity.  
 Using video self-modeling to treat public speaking anxiety is a novel method of 
treatment, and only single-subject designs have been used to determine its effectiveness at this 
time. Future research should include larger, randomized controlled trials to determine treatment 
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effectiveness. By utilizing a larger sample size, statistical power will be increased, and the 
implications of such a study would be strengthened. 
 More sensitive measures should be used to track treatment outcomes. Although some 
measures did indicate changes in scores, these changes were limited. In order to produce more 
meaningful and significant results, more sensitive scales should be developed to measure public 
speaking anxiety.  
 Although this study does support the hypothesis that VSM provides additional benefits in 
comparison to exposure alone, research in this area is mixed. Furthermore, these results were 
only significant with one measure, the PRCS-12. More research needs to be conducted 
comparing VSM to other treatments in order to determine its effectiveness. In addition, other 
types of statistical analyses should be conducted to determine significance. For example, split 
middle or celeration line techniques should be used. These methods are able to test treatment 
effectiveness when considering the current course of behavior. This is an important consideration 
because with exposure therapy, the participant generally continues to improve even when 
another component is added to treatment. By using split middle or celeration line, it can be 
determined if the additional component provides benefits that would not be elicited by the initial 
treatment.  
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Table 1 
Behaviors Indicative of Public Speaking Anxiety 
Quivering voice 
Speaking too fast 
Speaking too softly 
Stammering 
Using verbal crutches (e.g. "um" "uh") 
Extensive pauses (5 or more seconds) 
Throat clearing 
Heavy breathing (i.e. gasping) 
Lack of eye contact (5 or more seconds) 
Fidgeting 
Motionlessness (10 or more seconds) 
Swaying 
Note. All of these behaviors were removed during the editing process except lack of eye contact. 
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Appendix A 
Perception of Treatment Questionnaire 
 
In order to better understand what this experience was like, I would like to ask you a few 
questions about your perception of treatment and some of your outside behaviors during 
treatment. Your responses will be kept confidential, so please answer as truthfully as possible. 
Please answer "yes" or "no" and provide explanations if you like. 
 
1. The treatment was helpful. 
 
2. The treatment was a waste of time. 
 
3. The treatment helped reduced my public speaking anxiety. 
 
4. I feel more comfortable speaking in public now than I did before treatment. 
 
5. I would recommend this treatment to someone I knew who was experiencing public 
 speaking anxiety. 
 
6. Are you currently taking any medications to reduce anxiety? 
 If yes, how long have you been on medication? 
 
7. Are you currently taking any other steps to reduce anxiety (e.g. counseling, self-help 
 books, etc.)? 
 If yes, how long have you been seeking these services? 
 
8. Has any major event in your life occurred over the course of treatment that may have 
 impacted your anxiety level? 
 If yes, please briefly explain (e.g. moved to new house, recent breakup, etc.) 
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Appendix B 
Informed Consent 
Purpose 
You are requested to participate in research supervised by Dr. Daniel Houlihan on the treatment 
of public speaking anxiety. Participants will be asked to complete approximately 12 sessions, 
each lasting between 15 and 30 minutes, totaling approximately 6 hours. The goal of this study is 
to determine which of two treatment options is more effective. If you have any questions about 
the research, please contact Dr. Daniel Houlihan at daniel.houlihan@mnsu.edu 507-389-6308 or 
Emily Bartholomay at emily.bartholomay@mnsu.edu 701-793-0692. 
Procedures 
Screening. During the initial screening session, participants will be asked to complete a 
questionnaire. Individuals falling below the screening criteria (a score of 7 or lower on the 
PRCS) will not be invited to further participate in the study. All participants whose scores are 8 
or higher will be invited to participate in the study (12 sessions plus 2 follow up sessions). The 
screening session should take approximately 15 minutes. 
Baseline. During the first phase of the study (approximately 5 sessions), participants will fill out 
a battery of questionnaires, review a pre-written speech for five minutes, and give the speech to a 
small audience. Participants will be allowed to speak with the speech transcript as well as any 
notes they made in the five-minute preparation period. Each speech in this phase will be video 
recorded to be analyzed by the co-investigator. In order to reduce anxiety levels after each 
treatment, participants will be immediately debriefed. To further reduce anxiety, the audience for 
each session will include no more than five total audience members. This phase of the study 
should take between 45 minutes and 1 hour and 45 minutes per participant. 
Treatment. During the second phase of the study (approximately 7 sessions, plus follow-up 
sessions), participants will be subjected to the same procedures as during the first phase. The 
major change in the second phase is that participants will also be asked to watch an edited video 
recording of themselves giving the speech from the previous session. This video recording will 
be between two and five minutes with speech dysfluencies removed. The viewing of this video 
will occur immediately after filling out questionnaires and prior to reviewing and preparing the 
speech for the day's session. This phase of the study should take between 4 hours 15 minutes and 
5 hours 15 minutes per participant. 
Withdrawal 
Participation is voluntary. You have the option to withdraw from this study at any time, 
including both during and between sessions. You may withdraw from the study by informing 
either Dr. Houlihan or Emily Bartholomay in person, by email, by telephone, or by simply not 
attending further sessions. Participants will also be allowed to withdraw from this study at any 
point during the session by holding up a colored index card to indicate their desire to withdraw 
from treatment. 
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Participation or nonparticipation will not impact your relationship with Minnesota State 
University, Mankato. If you have any questions about the treatment of human participants and 
Minnesota State University, Mankato, contact the IRB Administrator, Dr. Barry Ries, at 507-
389-2321 or barry.ries@mnsu.edu. 
Confidentiality 
In order to protect participants' confidentiality, results will be published  and files will be stored 
under identification numbers as opposed to names. Records (including video recordings which 
will be saved on DVDs) will be kept for three years in University Square 107 located at 1600 
Warren St., Suite #6. After this time, all records will be destroyed by Dr . Houlihan. As a means 
to further protect participant confidentiality, only researchers involved in the study will have 
access to videotape recordings. More specifically, the primary and co-investigator and no more 
than two psychology students will be allowed access the videos. These students will be selected 
from the group of students involved in Dr. Houlihan's clinical psychology research team. In 
order to maintain participant confidentiality, all individuals involved in data collection/analysis 
and audience members will be required to sign a confidentiality agreement. The videos will not 
be used for any purpose other than for this study. 
Risks and Benefits 
The risks of participating in this survey are slightly more than are experienced in daily life. 
Participants are likely to experience temporarily elevated levels of anxiety due giving speeches 
and watching themselves perform these speeches on video recordings. In order to relieve these 
temporary increases in anxiety, a short debriefing session will occur after participants perform 
their speeches. Debriefing will include the co-investigator reminding participants of their right to 
withdraw at any time. Participants will also be given stress-management techniques to reduce 
this temporary anxiety. Participants will also engage in some of these techniques with the co-
investigator.  
The direct benefits for participating in this study are treatment of anxiety which may result in 
decreased levels of public speaking anxiety. Society may benefit from this research by decreased 
costs (fiscal and time) by reducing the amount of time spent in treatment by identifying the most 
effective treatment for public speaking anxiety.  
By signing this form, you are consenting to participate in this study and that you are at least 18 
years of age. A copy of this form will be made available to you. 
MSU IRBNet ID# 647777 
Date of MSU IRB approval: 10/30/2014 
 
 
__________________________________________   __________________ 
   Name        Date 
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